ACTA and Part III of TRIPS Compared by Frequency of Terms
ACTA is basically a re-write of Part III of the TRIPS, which is the part dealing with the enforcement of intellectual property rights. How do Part III of the TRIPS and ACTA compare in terms of the frequency of terms? Using the August 25, 2010 text, which includes in some cases duplication where there are competing versions of the text, the comparison now looks like this:
| Terms | Part III of TRIPS | ACTA |
Continue Reading
Part 1: Notes on the August 25, 2010 version of the ACTA consolidated textKEI has obtained a copy of the August 25, 2010 version of the ACTA consolidated negotiating text. This is Part 1 of our initial notes on the document. (Part 2 is available here.) (revised September 9, 2010) PreambleThe preamble in the August, 25, 2010 text includes 10 paragraphs, of which only 3 do not have brackets. Testinghttp://goo.gl/p6a15d https://docs.google.com/presentation/d/1ElI6rxLsq1SAlB69bsvti1_sK6A7W7pXP6Zmn7WM_lc/pub?start=false&loop=false&delayms=3000 Continue Reading Lunch with the ACTA negotiators, August 17, 2010On Tuesday, August 17, 2010, USTR organized a lunch between ACTA negotiators and civil society NGOs. There was not much notice. We received our invite to the lunch last Thursday. Representatives from KEI, Public Citizen, Oxfam, Public Knowledge and the American University program on intellectual property attended the event. The US Orphan Drug Tax CreditFrom the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading Notes and data points for prices of orphan productsFebruary 22, 2010., Matthew Herper, “The World’s Most Expensive Drugs,” Forbes. Genzyme’s web page on the cost of treatment. Some data points on Fabrazyme prices. 2004 prices for Replagal 2001 prices for Cerezyme. Myozyme/Lumizyme A 2007 Canadian analysis of (50… Continue Reading |